{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:11:37Z","timestamp":1790014297021,"version":"4.0.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012154","name":"Graduate Research and Innovation Projects of Jiangsu Province","doi-asserted-by":"publisher","award":["KYCX23_1926"],"award-info":[{"award-number":["KYCX23_1926"]}],"id":[{"id":"10.13039\/501100012154","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013058","name":"Jiangsu Provincial Key Research and Development Program","doi-asserted-by":"publisher","award":["ZD2021028"],"award-info":[{"award-number":["ZD2021028"]}],"id":[{"id":"10.13039\/501100013058","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genes & Diseases"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.gendis.2025.101816","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T15:22:06Z","timestamp":1755876126000},"page":"101816","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["N6-methyladenosine-modified circLPAR3 drives docetaxel resistance in prostate cancer by suppressing ferroptosis through the PCBP2\/CHAC1 axis"],"prefix":"10.1016","volume":"13","author":[{"given":"Yetao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongshan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyang","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5548-7845","authenticated-orcid":false,"given":"Qingyi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gendis.2025.101816_bib1","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology","volume":"21(10)","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.gendis.2025.101816_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114392","article-title":"Paclitaxel and docetaxel resistance in prostate cancer: molecular mechanisms and possible therapeutic strategies","volume":"160","author":"Hashemi","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.gendis.2025.101816_bib3","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387(10024)","author":"James","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.gendis.2025.101816_bib4","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36(11)","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gendis.2025.101816_bib5","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"399(10336)","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.gendis.2025.101816_bib6","article-title":"Mechanisms of docetaxel resistance in prostate cancer: the key role played by miRNAs","volume":"1875(1)","author":"Rizzo","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.gendis.2025.101816_bib7","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1158\/0008-5472.CAN-21-2988","article-title":"EIF4A3-Induced circARHGAP29 promotes aerobic glycolysis in docetaxel-resistant prostate cancer through IGF2BP2\/c-Myc\/LDHA signaling","volume":"82(5)","author":"Jiang","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.gendis.2025.101816_bib8","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40364-022-00393-1","article-title":"circCYP24A1 promotes docetaxel resistance in prostate cancer by upregulating ALDH1A3","volume":"10(1)","author":"Yin","year":"2022","journal-title":"Biomark Res"},{"key":"10.1016\/j.gendis.2025.101816_bib9","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s13046-022-02404-3","article-title":"Circ_0004087 interaction with SND1 promotes docetaxel resistance in prostate cancer by boosting the mitosis error correction mechanism","volume":"41(1)","author":"Chen","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.gendis.2025.101816_bib10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s11658-024-00628-z","article-title":"METTL3-mediated m(6)A modification of circGLIS3 promotes prostate cancer progression and represents a potential target for ARSI therapy","volume":"29(1)","author":"Cheng","year":"2024","journal-title":"Cell Mol Biol Lett"},{"key":"10.1016\/j.gendis.2025.101816_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2024.111510","article-title":"N6-methyladenosine-modified circRPS6KC1 regulated cellular senescence in prostate cancer via FOXM1\/PCNA axis","volume":"125","author":"Shu","year":"2025","journal-title":"Cell Signal"},{"key":"10.1016\/j.gendis.2025.101816_bib12","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/s41417-023-00650-x","article-title":"m6A-modified circABCC4 promotes stemness and metastasis of prostate cancer by recruiting IGF2BP2 to increase stability of CCAR1","volume":"30(10)","author":"Huang","year":"2023","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.gendis.2025.101816_bib13","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.7150\/ijbs.77133","article-title":"M6A-modified circRBM33 promotes prostate cancer progression via PDHA1-mediated mitochondrial respiration regulation and presents a potential target for ARSI therapy","volume":"19(5)","author":"Zhong","year":"2023","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.gendis.2025.101816_bib14","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1158\/1541-7786.MCR-22-0271","article-title":"m6A-Mediated biogenesis of circDDIT4 inhibits prostate cancer progression by sequestrating ELAVL1\/HuR","volume":"21(12)","author":"Kong","year":"2023","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.gendis.2025.101816_bib15","doi-asserted-by":"crossref","first-page":"966","DOI":"10.7150\/jca.89135","article-title":"n6-methyladenosine-modified circular RNA family with sequence similarity 126, member A affects cholesterol synthesis and malignant progression of prostate cancer cells by targeting microRNA-505-3p to mediate calnexin","volume":"15(4)","author":"Luo","year":"2024","journal-title":"J Cancer"},{"key":"10.1016\/j.gendis.2025.101816_bib16","article-title":"Ferroptosis induction improves the sensitivity of docetaxel in prostate cancer","volume":"2022","author":"Chen","year":"2022","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.gendis.2025.101816_bib17","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1038\/s41388-024-03057-6","article-title":"Cancer associated fibroblast secreted miR-432-5p targets CHAC1 to inhibit ferroptosis and promote acquired chemoresistance in prostate cancer","volume":"43(27)","author":"Zhao","year":"2024","journal-title":"Oncogene"},{"key":"10.1016\/j.gendis.2025.101816_bib18","article-title":"TFAP2C-Mediated lncRNA PCAT1 inhibits ferroptosis in docetaxel-resistant prostate cancer through c-Myc\/miR-25-3p\/SLC7A11 signaling","volume":"12","author":"Jiang","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.gendis.2025.101816_bib19","first-page":"D991","article-title":"NCBI GEO: archive for functional genomics data sets--update","volume":"41(Database issue)","author":"Barrett","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.gendis.2025.101816_bib20","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1038\/s41388-018-0602-8","article-title":"Dysregulation of p53-RBM25-mediated circAMOTL1L biogenesis contributes to prostate cancer progression through the circAMOTL1L-miR-193a-5p-Pcdha pathway","volume":"38(14)","author":"Yang","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.gendis.2025.101816_bib21","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3389\/fgene.2020.00062","article-title":"Identification of specific long non-coding ribonucleic acid signatures and regulatory networks in prostate cancer in fine-needle aspiration biopsies","volume":"11","author":"Li","year":"2020","journal-title":"Front Genet"},{"key":"10.1016\/j.gendis.2025.101816_bib22","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1080\/15476286.2019.1600395","article-title":"Circbank: a comprehensive database for circRNA with standard nomenclature","volume":"16(7)","author":"Liu","year":"2019","journal-title":"RNA Biol"},{"key":"10.1016\/j.gendis.2025.101816_bib23","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1093\/nar\/gkw104","article-title":"SRAMP: prediction of mammalian N6-methyladenosine (m6A) sites based on sequence-derived features","volume":"44(10)","author":"Zhou","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.gendis.2025.101816_bib24","doi-asserted-by":"crossref","first-page":"D571","DOI":"10.1093\/nar\/gkac935","article-title":"FerrDb V2: update of the manually curated database of ferroptosis regulators and ferroptosis-disease associations","volume":"51(D1)","author":"Zhou","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.gendis.2025.101816_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.150085","article-title":"Hederagenin promotes lung cancer cell death by activating CHAC1-dependent ferroptosis pathway","volume":"718","author":"Lu","year":"2024","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.gendis.2025.101816_bib26","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12951-023-01862-x","article-title":"Anti-CHAC1 exosomes for nose-to-brain delivery of miR-760-3p in cerebral ischemia\/reperfusion injury mice inhibiting neuron ferroptosis","volume":"21(1)","author":"Wang","year":"2023","journal-title":"J Nanobiotechnology"},{"key":"10.1016\/j.gendis.2025.101816_bib27","first-page":"777","article-title":"CHAC1 promotes cell ferroptosis and enhances radiation sensitivity in thyroid carcinoma","volume":"70(6)","author":"Yang","year":"2023","journal-title":"Neoplasma"},{"key":"10.1016\/j.gendis.2025.101816_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1458716","article-title":"CHAC1: a master regulator of oxidative stress and ferroptosis in human diseases and cancers","volume":"12","author":"Sun","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.gendis.2025.101816_bib29","doi-asserted-by":"crossref","first-page":"D92","DOI":"10.1093\/nar\/gkt1248","article-title":"starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data","volume":"42(Database issue)","author":"Li","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.gendis.2025.101816_bib30","doi-asserted-by":"crossref","first-page":"W72","DOI":"10.1093\/nar\/gkab393","article-title":"catRAPID omics v2.0: going deeper and wider in the prediction of protein-RNA interactions","volume":"49(W1)","author":"Armaos","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.gendis.2025.101816_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111719","article-title":"Advances in poly(rC)-binding protein 2: structure, molecular function, and roles in cancer","volume":"139","author":"Yuan","year":"2021","journal-title":"Biomed Pharmacother"},{"issue":"28","key":"10.1016\/j.gendis.2025.101816_bib32","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1200\/JCO.2016.72.1068","article-title":"Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III Trial-FIRSTANA","volume":"35","author":"Oudard","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gendis.2025.101816_bib33","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1001\/jamaoncol.2021.7298","article-title":"Efficacy and safety of autologous dendritic cell-based immunotherapy, docetaxel, and prednisone vs placebo in patients with metastatic castration-resistant prostate cancer: the VIABLE phase 3 randomized clinical trial","volume":"8(4)","author":"Vogelzang","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.gendis.2025.101816_bib34","first-page":"153","article-title":"Circular RNA LPAR3 targets JPT1 via microRNA-513b-5p to facilitate glycolytic activation but repress prostate cancer radiosensitivity","volume":"70(1)","author":"Chen","year":"2023","journal-title":"Acta Biochim Pol"},{"key":"10.1016\/j.gendis.2025.101816_bib35","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1080\/21655979.2022.2029109","article-title":"Circular RNA lysophosphatidic acid receptor 3 (circ-LPAR3) enhances the cisplatin resistance of ovarian cancer","volume":"13(2)","author":"Liu","year":"2022","journal-title":"Bioengineered"},{"key":"10.1016\/j.gendis.2025.101816_bib36","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12943-023-01782-2","article-title":"The role of m6A methylation in therapy resistance in cancer","volume":"22(1)","author":"Zhuang","year":"2023","journal-title":"Mol Cancer"},{"key":"10.1016\/j.gendis.2025.101816_bib37","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.ccell.2022.10.004","article-title":"The m(6)A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia","volume":"40(12)","author":"Weng","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.gendis.2025.101816_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116670","article-title":"Ferroptosis-inducing compounds synergize with docetaxel to overcome chemoresistance in docetaxel-resistant non-small cell lung cancer cells","volume":"276","author":"Huang","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.gendis.2025.101816_bib39","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.freeradbiomed.2018.07.020","article-title":"DMT1 and iron transport","volume":"133","author":"Yanatori","year":"2019","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.gendis.2025.101816_bib40","doi-asserted-by":"crossref","first-page":"17303","DOI":"10.1074\/jbc.M116.721936","article-title":"Iron export through the transporter ferroportin 1 is modulated by the iron chaperone PCBP2","volume":"291(33)","author":"Yanatori","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1016\/j.gendis.2025.101816_bib41","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1186\/s12951-024-02771-3","article-title":"Curcumin nanoparticles in heat stroke management","volume":"22(1)","author":"Guo","year":"2024","journal-title":"J Nanobiotechnology"},{"key":"10.1016\/j.gendis.2025.101816_bib42","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.7150\/ijbs.74546","article-title":"PHGDH inhibits ferroptosis and promotes malignant progression by upregulating SLC7A11 in bladder cancer","volume":"18(14)","author":"Shen","year":"2022","journal-title":"Int J Biol Sci"}],"container-title":["Genes & Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304225003058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304225003058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:47:46Z","timestamp":1790012866000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352304225003058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2352304225003058"],"URL":"https:\/\/doi.org\/10.1016\/j.gendis.2025.101816","relation":{},"ISSN":["2352-3042"],"issn-type":[{"value":"2352-3042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"N6-methyladenosine-modified circLPAR3 drives docetaxel resistance in prostate cancer by suppressing ferroptosis through the PCBP2\/CHAC1 axis","name":"articletitle","label":"Article Title"},{"value":"Genes & Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gendis.2025.101816","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101816"}}